Pre-Clinical \ Laboratory Research - Zyflamend
Zyflamend® (New Chapter, Inc., Brattleboro, VT):
Zyflamend is an amalgam comprised of 10 different herbal extracts (rosemary, turmeric, ginger, holy basil, green tea, hu zhang, Chinese goldthread, barberry, oregano, and Scutellaria baicalensis) and was originally chosen based upon their purported anti-inflammatory effects. Recent observations from a variety of both basic and clinical researchers suggest that inflammation and cancer may be intimately related. Our studies have demonstrated that this preparation does, indeed, inhibit major enzymes involved in initiating an inflammatory response (COX-1 and COX-2). We have also shown that Zyflamend inhibits prostate tumor cell growth and induces cell death by a process known as apoptosis. To understand the mechanisms through which Zyflamend is acting to suppress prostate cancer cells, we have continued our studies and have identified several key molecules in which Zyflamend appears to be acting upon. We have published our initial studies in an esteemed, peer reviewed journal, Nutrition and Cancer (Lawrence Erlbaum Associates, Mahwah, NJ) and we are currently preparing to present our latest results at the Society for Integrative Oncology’s annual meeting, November 9-11, 2006.
